FibroGen Archives -

GSK goes for gold as FDA starts review of daprodustat

Phil Taylor Akebia Therapeutics, anaemia, AstraZeneca, chronic kidney disease, daprodustat, FibroGen, GlaxoSmithKline, roxadustat, vadadustat 0 Comment

GlaxoSmithKline says the FDA has started its review of daprodustat for anaemia associated with chronic kidney disease (CKD),

GSK goes for gold as FDA starts review of daprodustat

https://pharmaphorum.com/news/fda-starts-review-of-gsks-kidney-drug-daprodustat/

Ardelyx’s-ambition-to-revolutionise-kidney-treatment

Market Access/ News/ News

After FDA snub, EMA backs FibroGen, Astellas’ roxadustat

Phil Taylor Akebia Therapeutics, anaemia, Astellas, chronic kidney disease, daprodustat, EU, FibroGen, GlaxoSmithKline, Haematology, regulatory approval, roxadustat, vadadustat 0 Comment

The EU regulator has approved FibroGen and Astellas Evrenzo for adults with anaemia caused by chronic kidney disease

After FDA snub, EMA backs FibroGen, Astellas’ roxadustat

https://pharmaphorum.com/news/after-fda-snub-ema-backs-fibrogen-astellas-roxadustat/

Market Access/ News/ News

FDA rejects FibroGen/AZ’s roxadustat, asking for new trial

Phil Taylor AstraZeneca, chronic kidney disease, daprodustat, fda, FibroGen, GlaxoSmithKline, nephrology, roxadustat 0 Comment

The FDA has demanded another clinical trial of FibroGen and AstraZeneca’s roxadustat for anaemia caused by chronic kidney

FDA rejects FibroGen/AZ’s roxadustat, asking for new trial

https://pharmaphorum.com/news/fda-rejects-fibrogen-azs-roxadustat-asking-for-new-trial/

Market Access/ News/ News

FDA adcomm turns down FibroGen, AZ’s roxadustat for CKD anaemia

Phil Taylor AstraZeneca, chronic kidney disease, daprodustat, fda, FibroGen, GlaxoSmithKline, nephrology, roxadustat 0 Comment

Safety concerns seem to have scuppered any hope of a near-term approval for FibroGen and AstraZeneca’s roxadustat for

FDA adcomm turns down FibroGen, AZ’s roxadustat for CKD anaemia

https://pharmaphorum.com/news/fda-adcomm-turns-down-fibrogen-azs-roxadustat-for-ckd-anaemia/

News

GSK’s kidney disease anaemia drug approved in Japan, taking on Astellas’ rival

Richard Staines anaemia, Astellas, AstraZeneca, chronic kidney disease, Duvroq, FibroGen, GlaxoSmithKline, Kyowa Kirin 0 Comment

GlaxoSmithKline’s drug for anaemia caused by chronic kidney disease daprodustat has been approved in Japan, taking on a recently approved rival from Astellas. Marketed

GSK’s kidney disease anaemia drug approved in Japan, taking on Astellas’ rival

https://pharmaphorum.com/news/gsk-kidney-disease-anaemia-drug-approved-in-japan-taking-on-astellas-rival/

News/ News/ R&D

AZ preps for US filing of kidney disease anaemia drug

Richard Staines Astellas, AstraZeneca, chronic kidney disease, FibroGen 0 Comment

AstraZeneca is gearing up for a US filing for its roxadustat, a potential drug for patients with anaemia

AZ preps for US filing of kidney disease anaemia drug

https://pharmaphorum.com/news/az-preps-for-us-filing-of-kidney-disease-anaemia-drugs/

Market Access/ News/ News

Astellas gets nod in Japan for roxadustat, ahead of GSK rival

Phil Taylor Astellas, chronic kidney disease, daprodustat, FibroGen, GlaxoSmithKline, roxadustat 0 Comment

Astellas has its first approval for roxadustat, getting a green light in Japan for the drug as a

Astellas gets nod in Japan for roxadustat, ahead of GSK rival

https://pharmaphorum.com/news/astellas-gets-nod-in-japan-for-roxadustat-ahead-of-gsk-rival/

News/ News/ R&D

AstraZeneca shows cardiovascular safety for roxadustat

George Underwood AstraZeneca, chronic kidney disease, FibroGen, kidney, roxadustat 0 Comment

AstraZeneca has announced that pooled analyses of the phase III trials for its kidney disease drug roxadustat confirm

AstraZeneca shows cardiovascular safety for roxadustat

https://pharmaphorum.com/news/astrazeneca-shows-cardiovascular-safety-for-roxadustat/

News/ R&D

Galapagos and FibroGen drugs offer hope in IPF

Richard Staines Boehringer Ingelheim, FibroGen, Galapagos, idiopathic pulmonary fibrosis, respiratory, Roche 0 Comment

Drugs improve on existing medicines from Boehringer and Roche.

Galapagos and FibroGen drugs offer hope in IPF

https://pharmaphorum.com/news/galapagos-fibrogen-ipf/

Trending

FibroGen

Login